The CDC sees signs of a late summer COVID wave. AMA’s Vice President of Science, Medicine and Public Health, Andrea Garcia, JD, MPH, discusses the rise in cases, whether there is cause for concern and who is most at risk. Plus, the latest news about Alpha-gal syndrome (AGS) cases and the FDA approval of the second over-the-counter naloxone nasal spray, RiVive. American Medical Association CXO Todd Unger hosts.

💻 Access CDC AGS resources and Alpha-gal Syndrome Clinician Training (CME credit), here: https://www.cdc.gov/ticks/alpha-gal/resources/index.html

🩺 The AMA is your powerful ally in patient care. Join now: https://bit.ly/AMAJoinRenew